Apr 27, 2015
iCo Therapeutics Announces Year End 2014 Financial Results
Nov 28, 2014
iCo Therapeutics Announces Third Quarter 2014 Financial Results and Corporate Update
Nov 4, 2014
iCo Therapeutics Announces Oral Amphotericin Presentations at AAPS

View All News (+)

Enter Your Email to Sign Up for
iCo Therapeutics Updates

About iCo Therapeutics

iCo Therapeutics in-licenses and redefines existing drug candidates or generics by employing reformulation and delivery technologies for new or expanded use indications. The Company is advancing an oral delivery program, beginning with Amphoterincin B, utilizing a known anti-fungal drug to treat life-threatening infectious diseases and treat latent HIV reservoirs. iCo has a partnership with Immune Pharmaceuticals for iCo-008 which is in clinical studies for bullous pemphigoid and ulcerative colitis, while maintaing ophthalmic rights. iCo-007 is a C-Raf inhibitor asset, not currently in development. iCo trades on the TSX Venture Exchange under the symbol "ICO" and the OTCQX under the symbol "ICOTF".

Copyright 2010 ICO Therapeutics | Disclaimer